Product Description
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ObsEva
Company Location: PLAN-LES-OUATES V8 1228
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Infertility|Pregnancy Outcomes
Phase 2: Obstetric Labor, Premature|Infertility|Pregnancy Outcomes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2014-002254-40 |
IMPLANT | P2 |
Completed |
Pregnancy Outcomes |
2016-11-29 |
2022-03-13 |
Treatments |
|
2014-003217-28 |
TERM | P2 |
Completed |
Obstetric Labor, Premature |
2016-10-28 |
2022-03-13 |
Treatments |
|
NCT02326142 |
TERM | P2 |
Terminated |
Obstetric Labor, Premature |
2016-10-01 |
2019-03-20 |
Treatments |
|
NCT02310802 |
IMPLANT | P2 |
Completed |
Infertility |
2015-11-01 |
2019-03-20 |
||
2018-002910-11 |
IMPLANT 4 | P3 |
Completed |
Pregnancy Outcomes |
2020-11-19 |
2025-06-22 |
Treatments |
|
NCT03758885 |
IMPLANT4 | P3 |
Completed |
Infertility |
2019-11-21 |
13% |
2021-09-10 |
|
2016-004266-25 |
2016-004266-25 | P3 |
Completed |
Pregnancy Outcomes |
2019-02-19 |
2022-03-13 |
Treatments |
|
NCT03081208 |
IMPLANT2 | P3 |
Completed |
Infertility |
2018-03-21 |
17% |
2019-12-25 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |